Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621773 | 0.87 | PTGS2 (0.48) | PTGS2PTGS1ALOX5APFEN1HSD11B1 | |
| SCHEMBL6904881 | 0.80 | PTGS2 (0.68) | PTGS2PTGS1ALOX5ALOX5APFEN1 | |
| SCHEMBL851339 | 0.79 | PTGS2 (0.71) | PTGS2PTGS1 | |
| Sulfamide SCHEMBL4639024 | 0.77 | PTGS2 (0.45) | PTGS2PTGS1MAOA | |
| SCHEMBL7515254 | 0.77 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL5668728 | 0.76 | PTGS1 (0.41) | PTGS2PTGS1ALOX5ALDH1A1POLB | |
| SCHEMBL8974381 | 0.71 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL9744628 | 0.71 | PTGS2 (0.37) | PTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL214628 | 0.71 | PTGS2 (0.56) | PTGS2PTGS1MAOA | |
| SCHEMBL6050700 | 0.71 | PTGS2 (0.55) | PTGS2PTGS1ALOX5HSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088814-B2 | Administering a cyclooxygenase inhibitor; treating schizophrenia, delusional disorders, affective disorders, autism or tic disorders | MUELLER NORBERT (DE) | 2012-01-03 | — | — | US | disclosed |
| US-20030130334-A1 | Methods and compositions for the treatment of psychiatric disorders | MULLER NORBERT | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130334-A1 | Methods and compositions for the treatment of psychiatric disorders | TPH2, MAOB, PTGS2 | PTGS2 3/4885PTGS1 15/4885ALOX5 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.